tetano
Editor, Senior Moderator
Semin Respir Crit Care Med
. 2023 Feb;44(1):100-117.
doi: 10.1055/s-0042-1759778. Epub 2023 Jan 16.
Glucocorticoid Therapy in COVID-19
Francesco Amati[SUP] 1 2 [/SUP], Antonio Tonutti[SUP] 2 [/SUP], John Huston[SUP] 3 [/SUP], Charles S Dela Cruz[SUP] 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality in pandemic proportions. Inflammation in response to the infection contributes to the pathogenesis of pneumonia. This review will discuss prior studies on the use of glucocorticoids to treat respiratory infections, the rationale for the use glucocorticoids in COVID-19, and review of existing data. We will also highlight outstanding research questions for future studies.
. 2023 Feb;44(1):100-117.
doi: 10.1055/s-0042-1759778. Epub 2023 Jan 16.
Glucocorticoid Therapy in COVID-19
Francesco Amati[SUP] 1 2 [/SUP], Antonio Tonutti[SUP] 2 [/SUP], John Huston[SUP] 3 [/SUP], Charles S Dela Cruz[SUP] 3 [/SUP]
Affiliations
- PMID: 36646089
- DOI: 10.1055/s-0042-1759778
Abstract
Coronavirus disease 2019 (COVID-19) pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality in pandemic proportions. Inflammation in response to the infection contributes to the pathogenesis of pneumonia. This review will discuss prior studies on the use of glucocorticoids to treat respiratory infections, the rationale for the use glucocorticoids in COVID-19, and review of existing data. We will also highlight outstanding research questions for future studies.